BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim H, Hong E, Kim J, Lee W. Solution Structure of Human Orexin-A: Regulator of Appetite and Wakefulness. BMB Reports 2004;37:565-73. [DOI: 10.5483/bmbrep.2004.37.5.565] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Hong C, Byrne NJ, Zamlynny B, Tummala S, Xiao L, Shipman JM, Partridge AT, Minnick C, Breslin MJ, Rudd MT, Stachel SJ, Rada VL, Kern JC, Armacost KA, Hollingsworth SA, O'Brien JA, Hall DL, McDonald TP, Strickland C, Brooun A, Soisson SM, Hollenstein K. Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation. Nat Commun 2021;12:815. [PMID: 33547286 DOI: 10.1038/s41467-021-21087-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
2 Karhu L, Magarkar A, Bunker A, Xhaard H. Determinants of Orexin Receptor Binding and Activation-A Molecular Dynamics Study. J Phys Chem B 2019;123:2609-22. [PMID: 30786708 DOI: 10.1021/acs.jpcb.8b10220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 German NA, Decker AM, Gilmour BP, Thomas BF, Zhang Y. Truncated Orexin Peptides: Structure-Activity Relationship Studies. ACS Med Chem Lett 2013;4:1224-7. [PMID: 24707347 DOI: 10.1021/ml400333a] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
4 Sakai N, Matsumura M, Lin L, Mignot E, Nishino S. HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy. Sci Rep 2019;9:477. [PMID: 30679597 DOI: 10.1038/s41598-018-36942-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
5 Yin J, Babaoglu K, Brautigam CA, Clark L, Shao Z, Scheuermann TH, Harrell CM, Gotter AL, Roecker AJ, Winrow CJ, Renger JJ, Coleman PJ, Rosenbaum DM. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors. Nat Struct Mol Biol 2016;23:293-9. [PMID: 26950369 DOI: 10.1038/nsmb.3183] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 13.0] [Reference Citation Analysis]
6 Putula J, Pihlajamaa T, Kukkonen JP. Calcium affects OX1 orexin (hypocretin) receptor responses by modifying both orexin binding and the signal transduction machinery. Br J Pharmacol 2014;171:5816-28. [PMID: 25132134 DOI: 10.1111/bph.12883] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
7 Black SW, Yamanaka A, Kilduff TS. Challenges in the development of therapeutics for narcolepsy. Prog Neurobiol 2017;152:89-113. [PMID: 26721620 DOI: 10.1016/j.pneurobio.2015.12.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
8 Liolios C, Patsis C, Lambrinidis G, Tzortzini E, Roscher M, Bauder-Wüst U, Kolocouris A, Kopka K. Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors. Mol Pharm 2022. [PMID: 35467350 DOI: 10.1021/acs.molpharmaceut.2c00070] [Reference Citation Analysis]